

Physician Views: Assessing Competition in the Idiopathic Pulmonary Fibrosis Market

<https://marketpublishers.com/r/PFFE57A7160EN.html>

Date: May 2015

Pages: 0

Price: US\$ 695.00 (Single User License)

ID: PFFE57A7160EN

Abstracts

Late 2014/early 2015 witnessed a flurry of activity in the idiopathic pulmonary fibrosis (IPF) space: Roche's \$8.3 billion acquisition of InterMune – providing access to the IPF treatment Esbriet – and subsequent FDA approval of Esbriet and Boehringer Ingelheim's competing therapy Ofev in mid-October.

In January, Ofev was approved for use in the EU, with Esbriet's European label updated in February to reflect a mortality benefit demonstrated in Phase III studies (Esbriet having originally been approved in the region in 2011).

FirstWord Pharma has been tracking developments in the IPF market via a number of previous Physician View polls, focusing on the respective clinical profiles of Esbriet and Ofev, anticipated usage in the US market and launch of Ofev in the EU market.

With Esbriet and Ofev having now been available in the US market for over six months, and with the European IPF market evolving with the availability of Boehringer Ingelheim's product and new labelling for Esbriet, we are asking pulmonologists based in the US and EU5 markets to provide their initial assessment of these two breakthrough drugs for IPF.

Specifically we are asking pulmonologists...

Of the newer treatments approved for IPF – Esbriet (pirfenidone) and Ofev (nintedanib) – which is your favoured drug (the one you prescribe the most) and why?

Esbriet – based on clinical profile

Esbriet – based on patient access programme

Esbriet – based on price

Esbriet – Other (please state)

Ofev – based on clinical profile

Ofev – based on patient access programme

Ofev – based on price

Ofev – other (please state)

I use both products equally

I have no choice in selecting either product but prefer Esbriet

I have no choice in selecting either product but prefer Ofev

How satisfied are you with physician/patient access to Esbriet?

Not at all satisfied

Slightly satisfied

Moderately satisfied

Very satisfied

Completely satisfied

How satisfied are you with physician/patient access to Ofev?

Not at all satisfied

Slightly satisfied

Moderately satisfied

Very satisfied

Completely satisfied

In 12 months' time, to what percentage of eligible IPF patients would you anticipate prescribing Esbriet to?

In 12 months' time, to what percentage of eligible IPF patients would you anticipate prescribing Ofev to?

I would like to order

Product name: Physician Views: Assessing Competition in the Idiopathic Pulmonary Fibrosis Market

Product link: <https://marketpublishers.com/r/PFFE57A7160EN.html>

Price: US\$ 695.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/PFFE57A7160EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970